A Phase I/II, multicenter study, evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodglin lymphoma

Study title: 
A Phase I/II, multicenter study, evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodglin lymphoma
Long title: 
A Phase I/II, multicenter study, evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodglin lymphoma
Date receipt dossier: 
6 Sep 2021
EU record number: 
CP0201-NHL
EudraCT number: 
2021-003272-13
Pharmaceutical study code: 
19CP02
Company / Sponsor: 
CellPoint B.V.
Phase: 
I/II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Lymphomas non-Hodgkin's B-cell
Therapeutic approach: 
Immunotherapy
Genetic modification: 
CD19-CAR
Method of transfer of nucleic acid of interest: 
Lentiviral vector
Administered biological material: 
Autologous T-cells transduced with lentiviral vectors against CD19-CAR
Route of administration: 
Intravenous
Locations in Belgium: 
CHU de Liège, UZA
Type of procedure: 
Contained use only
Current status: 
Authorized